advanced search

INJECTION

FRICTIONLESS ENGAGEMENT: HOW GX INMONIT™ CAN SIMPLIFY SELF-INJECTION AND STRENGTHENS PATIENT ADHERENCE
CONNECTIVITY
Giacomo Bruno
Gerresheimer
FRICTIONLESS ENGAGEMENT: HOW GX INMONIT™ CAN SIMPLIFY SELF-INJECTION AND STRENGTHENS PATIENT ADHERENCE
Dr Giacomo Bruno and Simon Buerdel consider the causes of patient non-adherence and its subsequent effects on healthcare systems, going on to present the solutions created by Gerresheimer to address the patient experience across treatment types.
TESTING AUTOINJECTORS ACCORDING TO ISO 11608-5 TO INCREASE RELIABILITY AND BOOST EFFICIENCY
PREFILLED SYRINGES
Wolfgang Moersch
ZwickRoell
TESTING AUTOINJECTORS ACCORDING TO ISO 11608-5 TO INCREASE RELIABILITY AND BOOST EFFICIENCY
Wolfgang Moersch discusses the role of automation in testing injection devices – including autoinjectors, pen injectors and on-body injectors – and how advanced testing software and robotics solutions can provide more accurate and consistent testing results.
SAFETY BY DESIGN FOR DRUG DELIVERY DEVICES
PREFILLED SYRINGES
Dr Stefan Schreiber
Scherdel Medtec
SAFETY BY DESIGN FOR DRUG DELIVERY DEVICES
Professor Stefan Schreiber, Dr Theo Wember and Sebastian Block discuss how using Design of Experiments methodology can provide insights into the manufacturing process of power springs that can enable manufacturers to more robustly control variables and produce more consistent outputs.
FROM CONCEPT TO SERIES PRODUCTION – ACCELERATING INDUSTRIALISATION IN MEDTECH
PREFILLED SYRINGES
Matthias Müller
Contexo
FROM CONCEPT TO SERIES PRODUCTION – ACCELERATING INDUSTRIALISATION IN MEDTECH
Matthias Müller and Sven Müller discuss Contexo and Probotec's combined approach to scaling drug-device combination products from laboratory prototypes to fully validated GMP commercial-scale production lines.
Interview: New But Not News – A Smooth Transition to USP <382> with Established Expertise
INTERVIEW
Dr Aurelie Rebuffet
BD (Becton Dickinson & Company)
Interview: New But Not News – A Smooth Transition to USP <382> with Established Expertise
Dr Aurélie Rebuffet and Virginie Jeymond, discuss the new requirements set out in the US Pharmacopeia (USP) Chapter <382>, including the shift towards assessing the drug-device combination product as a holistic whole and how ZebraSci and BD can support pharma companies in complying with USP <382>.
BUILDING STRATEGIC PARTNERSHIPS FOR EARLY-STAGE DRUG DELIVERY DEVICE TESTING
INJECTION
Landon Goldfarb
Instron
BUILDING STRATEGIC PARTNERSHIPS FOR EARLY-STAGE DRUG DELIVERY DEVICE TESTING
Landon Goldfarb considers the importance of relationships between formulation and delivery teams for pharmaceutical innovation, highlighting a framework to differentiate between an equipment supplier and a testing partner, outlining the system capabilities and organisational competencies required to create effective early device-development teams.
DEVELOPMENTAL ADVANTAGES IN INJECTABLE COMBINATION DRUG PRODUCTS
EXPERT VIEW
Dr Oliver Eden
DEVELOPMENTAL ADVANTAGES IN INJECTABLE COMBINATION DRUG PRODUCTS
Oliver Eden and Travis Webb consider how regulatory considerations and patient-centric device designs are transforming the landscape of self-administered injectable drugs.
Interview: DARE IDDS – A Long-Term Subcutaneously Implanted Drug Delivery Device
INTERVIEW
Liz Proos
Daré Bioscience
Interview: DARE IDDS – A Long-Term Subcutaneously Implanted Drug Delivery Device
Liz Proos and Ashley Hawson talk exclusively with ONdrugDelivery's Guy Furness about the DARE Intelligent Drug Delivery System – an advanced, connected implantable device that delivers programmable doses for up to a decade – its place in the market, the challenges faced during its design and its potential as novel drug delivery device.
DESIGNING SUSTAINABLE DRUG DELIVERY DEVICE PACKAGING: TRENDS, CHALLENGES AND REGULATORY IMPLICATIONS
EXPERT VIEW
Angela Shotton
DESIGNING SUSTAINABLE DRUG DELIVERY DEVICE PACKAGING: TRENDS, CHALLENGES AND REGULATORY IMPLICATIONS
Angela Shotton and Nic Hunt, look at the evolving landscape of the pharmaceutical packaging landscape and consider how the industry is meeting sustainability and regulatory requirements.
FRACTIONAL INVESTMENT IN DEVICE PLATFORMS – A NEW FUNDING PARADIGM
EXPERT VIEW
Paul Jansen
FRACTIONAL INVESTMENT IN DEVICE PLATFORMS – A NEW FUNDING PARADIGM
Drawing on his extensive experience in the drug delivery device industry, Paul Jansen considers how funding for delivery device development has shifted over the years, from the pre-platform model to currently accepted practice and looks forward to how it may further evolve to support the development of novel devices in the biologics space and beyond.
THE PLATFORM PARADOX: DEVICE DEVELOPMENT CHALLENGES WITHIN FAST EVOLVING DRUG DISCOVERY PIPELINES
EXPERT VIEW
Tim Quigg
THE PLATFORM PARADOX: DEVICE DEVELOPMENT CHALLENGES WITHIN FAST EVOLVING DRUG DISCOVERY PIPELINES
Tim Quigg, Mariam Al-Amari and Joel Gresham discuss how to enable high-dose delivery for novel biologics, using ex vivo and in silico approaches to accelerate drug-device development and improve device performance, thus de-risking projects and saving costs.
FROM BRICK-DUST DRUGS TO BREAKTHROUGHS: TRANSFORMING DRUG DELIVERY WITH NOVEL EXCIPIENTS
FORMULATION
Dr Liliana Miinea
Lubrizol
FROM BRICK-DUST DRUGS TO BREAKTHROUGHS: TRANSFORMING DRUG DELIVERY WITH NOVEL EXCIPIENTS
Dr Liliana Miinea of Lubrizol discusses how next-generation excipients can help formulators realise the potential of promising but poorly soluble drug candidates, including Lubrizol’s Apisolex™ and Apinovex™ polymer excipients for parenteral and oral applications.
USING OXYCAPT™ MULTILAYER PLASTIC VIAL FOR GENE AND CELL THERAPIES STORED IN DRY ICE AND LIQUID NITROGEN
PREFILLED SYRINGES
Hiroki Hasegawa
Mitsubishi Gas Chemical
USING OXYCAPT™ MULTILAYER PLASTIC VIAL FOR GENE AND CELL THERAPIES STORED IN DRY ICE AND LIQUID NITROGEN
Hiroki Hasegawa and Tomohiro Suzuki consider the various challenges presented by cold-chain logistics to both traditional glass vials and many cyclo-olefin polymer alternatives, and how Mitsubishi Gas Chemical's  OXYCAPT™ vials offer significant advantages for maintaining container closure integrity compared with other materials on the market.
PRIMARY PACKAGING AND ADMINISTRATION OF CELL THERAPIES: CURRENT TRENDS AND CHALLENGES
CGT
Krishnendu khan
West Pharmaceutical Services
PRIMARY PACKAGING AND ADMINISTRATION OF CELL THERAPIES: CURRENT TRENDS AND CHALLENGES
Dr Krishnendu Khan and Henry Nguyen of West Pharmaceutical Services examine factors to consider when designing and selecting primary packaging for cell therapies, exploring the effects of cryogenic storage on packaging and cells, while highlighting the diverse delivery methods and applications for these therapies.
EVOLVING ELASTOMER STOPPER TECHNOLOGIES FOR A CHANGING REGULATORY LANDSCAPE
CGT
Dr Laure-Helene Guillemot
Aptar Pharma
EVOLVING ELASTOMER STOPPER TECHNOLOGIES FOR A CHANGING REGULATORY LANDSCAPE
Dr Laure-Hélène Guillemot and Edouard Pagnoud assess the impact of the per- and polyfluoroalkyl substances ban on elastomer stoppers and the resulting extractables and leachables challenges, highlighting how Aptar Pharma is developing new solutions to meet both regulatory expectations and customer needs.
SHEAR RELIEF: MINIMISING SHEAR STRESS IN CGT PRODUCTION
EXPERT VIEW
Dr Ethan Miller
SHEAR RELIEF: MINIMISING SHEAR STRESS IN CGT PRODUCTION
Dr Ethan Miller examines the manufacturing of cell and gene therapies where shear stress can impact cells and explores strategies to mitigate such damage, helping to ensure that therapies retain their viability, functionality and therapeutic potency from production through to administration.
ENHANCING DRUG DELIVERY WITH INNOVATIVE SOFT MIST INHALER TECHNOLOGY
PULMONARY
Dr Nicolas Buchmann
Resyca
ENHANCING DRUG DELIVERY WITH INNOVATIVE SOFT MIST INHALER TECHNOLOGY
Dr Nicolas Buchmann and Bernhard Müllinger, discuss the capabilities of soft mist inhalers in terms of usability for patients, sustainability, compatibility with biologics and cost-effective delivery, showcasing these advantages in Resyca’s Pre-Filled Syringe Inhaler (PFSI).
CLOSING THE LOOP: DESIGNING THE FUTURE OF SUSTAINABLE DRUG DELIVERY DEVICES
SUSTAINABILITY
Thuysi Dao
Ypsomed
CLOSING THE LOOP: DESIGNING THE FUTURE OF SUSTAINABLE DRUG DELIVERY DEVICES
Thuysi Dao outlines a two-pronged approach to improving the sustainability profile of drug delivery devices, combining sustainable device design with real-world take-back and recycling initiatives, and explores how Ypsomed’s new YpsoLoop autoinjector platform embodies this vision.
Interview: A Structured Approach to the Eco-Design Process
INTERVIEW
Fabien de Coninck
Aptar Pharma
Interview: A Structured Approach to the Eco-Design Process
Fabien De Coninck and Bruno Morchain discuss Aptar Pharma’s eco-design philosophy with ONdrugDelivery’s Guy Furness. They cover how Aptar Pharma has implemented lifecycle assessments as a key tool to elucidate the environmental footprint of the company’s rubber components for primary packaging for injectable systems, including how they tackled the unique challenges presented by the complex, proprietary formulations involved in elastomer component design.
ADOPTION OF SUSTAINABILITY PRACTICES WITHIN SUBCUTANEOUS DRUG DELIVERY: INDUSTRY INSIGHTS
PHARMA VIEW
Conor O'Neill
GSK
ADOPTION OF SUSTAINABILITY PRACTICES WITHIN SUBCUTANEOUS DRUG DELIVERY: INDUSTRY INSIGHTS
Conor O’Neill (GSK), Duncan Paterson (AstraZeneca) and Dr Monica Adams (GSK) come together to discuss a recent study conducted by the Subcutaneous Drug Development & Delivery Consortium among its member organisations, digging into the pharmaceutical industry’s progress and priorities when it comes to improving the environmental impact of subcutaneous medicines.
THE COMPASS FOR INNOVATION: REGULATORY AFFAIRS AT YPSOMED
INJECTION
Stefanie Stark
Ypsomed
THE COMPASS FOR INNOVATION: REGULATORY AFFAIRS AT YPSOMED
Stefanie Stark and Sandra Schaerer-Lickova highlight how regulatory strategy enables ideas to become solutions, supports development through the product lifecycle and helps ensure that patients worldwide obtain safe and timely access.
PROVING THE DESIGN SPACE: ADVANCING THE DEVELOPMENT OF SYRINGE-DEVICE COMBINATIONS
PREFILLED SYRINGES
Enrico Barichello
Stevanato Group
PROVING THE DESIGN SPACE: ADVANCING THE DEVELOPMENT OF SYRINGE-DEVICE COMBINATIONS
Enrico Barichello and Courtney Nicholas Sutton the innovative combination of the Molly® autoinjector with Alba® and Nexa® prefilled syringes, which addresses the need to streamline device approval by establishing comprehensive compatibility testing, collaboration between suppliers and validated solutions for drug delivery.
AUTOINJECTORS VERSUS ON-BODY SYSTEMS: THE FUTURE OF LARGE-VOLUME DELIVERY
EXPERT VIEW
Dr Alex Vasiev
AUTOINJECTORS VERSUS ON-BODY SYSTEMS: THE FUTURE OF LARGE-VOLUME DELIVERY
Dr Alex Vasiev and Dr Ethan Miller weigh up the benefits and costs of using on-body injectors versus autoinjectors, discussing delivery, design and patient population variability alongside recent advances in on-body injector development.
Interview: Steven Kaufman. Delivering the Future – Inside the World of Autoinjector Innovation
INTERVIEW
Steven Kaufman
Portal Instruments
Interview: Steven Kaufman. Delivering the Future – Inside the World of Autoinjector Innovation
Steven Kaufman talks with ONdrugDelivery’s Guy Furness about the world of autoinjectors, looking at the current status quo in the industry, using Portal’s PRIME Nexus™ smart reusable electromechanical autoinjector as a lens to bring into focus how things have changed and where they might be going.
Top